Home
About Us
About Us

Beijing Northland Biotechnology Co., Ltd. is an innovative biopharmaceutical company specializing in the research, development, production, and sales of gene therapy drugs, recombinant protein drugs, and ophthalmic drugs.
News
R&D
R&D

Primarily dedicated to the research, development, and industrialization of novel bioengineered drugs in areas such as cardiovascular diseases, metabolic disorders, rare diseases, and ophthalmic diseases.
Investor Relations
Investor Relations

Guided by the principle of “Creating Value, Serving Health,” the company is committed to becoming an innovative biopharmaceutical enterprise, contributing to the advancement of China’s pharmaceutical industry and the well-being of humanity.
Our Businesses
- NL-PHARM
- Hounland
Our Businesses

Owns Beijing Northland Biopharmaceutical Co., Ltd. and Beijing Huons Pharmaceutical Co., Ltd., which are engaged in bioengineering drugs and ophthalmic products, respectively.

Language

Donaperminogene Seltoplasmid Injection Makes Its Debut at the Huimai Vascular Disease Forum—Innovative Therapy Offers New Approaches for Clinical Treatment of CLI

发布时间：2025-12-18

From December 12 to 13, 2025, the Inaugural Conference of the Specialized Committee on Arteriovenous and Peripheral Vascular Diseases of the China Association for Geriatric Health Care, together with the Huimei Vascular Disease Forum, was successfully held in Hefei, Anhui Province. The conference was organized by the China Association for Geriatric Health Care and co-organized by the Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine and the Second Affiliated Hospital of Anhui Medical University. The event brought together top vascular disease experts from across China, focusing on cutting-edge developments in vascular diseases, jointly exploring China’s comprehensive system for the prevention and treatment of vascular diseases, and working together to build a robust defense for the vascular health of the elderly.

2025-12

The discussion meeting on the Phase IIc clinical trial protocol for Recombinant Human Thymosin β4 Injection (NL005) was successfully held.

发布时间：2025-12-11

On December 9, 2025, the "Summary Meeting of Phase IIb Clinical Trial and Discussion on Phase IIc Clinical Trial Protocol for Recombinant Human Thymosin β4 Injection (NL005)," hosted by Beijing Northland Biotechnology Co., Ltd., was successfully held in Beijing. The meeting adopted a hybrid online-and-offline format, bringing together more than 20 experts from the fields of cardiovascular medicine and magnetic resonance imaging, representing over 10 clinical research centers across China, as well as representatives from the sponsor and the CRO team. The attending experts conducted in-depth scientific discussions and feasibility assessments centered on the previous research findings of NL005 and the design of the Phase IIc clinical trial protocol.

2025-12

Donaperminogene Seltoplasmid Injection Shines at the First Academic Annual Conference of the Vascular Surgery Branch of the National Association for Health Industry Enterprise Management

发布时间：2025-12-08

From December 5 to 6, 2025, the inaugural Academic Annual Conference of the Vascular Surgery Branch of the National Health Industry Enterprise Management Association, together with the 2025 Academic Symposium on New Advances in the Diagnosis and Treatment of Diabetic Foot, will be grandly held in Beijing. Co-organized by the Zhongguancun Precision Medicine Foundation and other institutions, the conference has drawn together top experts and scholars from various disciplines—including vascular surgery, wound healing, and endocrinology—providing a platform for them to discuss the cutting-edge developments in their fields. At this conference, Mr. Xu Songshan, Chairman of our company, was appointed as a director of the Vascular Surgery Branch of the National Health Industry Enterprise Management Association, thanks to his profound industry background.

2025-12

Researchers involved in the Phase III clinical trial of Donaperminogene Seltoplasmid Ingection have been invited to attend the LINC Conference in Germany and deliver a keynote presentation.

发布时间：2025-12-07

Recently, Dr. Xi Xiao from the Department of Vascular Surgery at Peking Union Medical College Hospital received an invitation from the organizers of LINC (Leipzig Interventional Course) to attend the annual LINC conference in Leipzig, Germany, on January 29, 2026, and deliver a keynote presentation. Dr. Xi Xiao is one of the principal investigators of the Phase III clinical trial for our company’s innovative gene therapy drug, “Donaperminogene Seltoplasmid Ingection.” At the LINC conference, he will give a keynote speech to comprehensively present the clinical research findings on “Donaperminogene Seltoplasmid Ingection” for the treatment of critical limb ischemia (CLI)—a severe lower-limb vascular disease. He will share with global vascular surgeons and peers the progress and achievements made in the development of this China-originated, clinically-led innovative gene therapy drug, as well as the latest updates on its clinical trials.

2025-12

Research findings on NORTHLAND's independently developed recombinant human thymosin β4 (rhTB4) have been published in a top international journal, revealing a novel cardioprotective mechanism and clinical potential.

发布时间：2025-12-04

Recently, the top international cardiovascular journal, Cardiovascular Research, published online a groundbreaking research paper led by Professor Dou Kefei’s team from Fuwai Hospital, Chinese Academy of Medical Sciences, and featuring Beijing Northland Biotechnology Co., Ltd. (hereinafter referred to as “NORTHLAND”)—a core product currently under development, recombinant human thymosin β4 (rhTB4)—for the treatment of acute myocardial infarction. The paper has an impact factor of 13.3.

2025-12

Phase III result for Donaperminogene Seltoplasmid Ingection was unveiled at the 2025 MEC Conference, where experts jointly explored new strategies for CLI treatment.

发布时间：2025-12-02

From November 28 to 29, 2025, the 2025 Microcirculatory Vascular Medicine (Chaoyang) Development Conference will be grandly held at the Beijing International Conference Center. As the year’s most significant academic event in the field of microcirculatory vascular medicine, the conference is jointly organized by the Chinese Microcirculation Association and the Beijing Health Promotion Association, and co-organized by the Specialist Committee on Peripheral Vascular Diseases of the Chinese Microcirculation Society and Beijing Chaoyang Hospital Affiliated to Capital Medical University. The conference has attracted top experts and scholars from various disciplines—including microcirculation research, vascular surgery, and cardiovascular medicine—both from China and abroad, who have gathered to discuss the cutting-edge developments in this field.

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Friendly Links: Baidu | NORTHLAND

Contact Information

Address: Room A406, Zhongguancun Biomedical Park, No. 5 Kaituo Road, Shangdi, Haidian District, Beijing

Hotline: +86 010-82890893

Email: northland@northland-bio.com

Website: www.northland-bio.com

Complaints Reporting Hotline: +86 010-82890893-8031

Complaints Reporting Email: pv@northland-bio.com

ADR information: Click to Download

Northland is an innovative biopharmaceutical company specializing in the R&D, manufacturing and sales of gene therapy drugs, recombinant protein drugs and ophthalmic medications.

Web site

NL-BIO

Scientific Research on Lower Limb Ischemia

NL003

Myocardial Infarction Scientific Research

NL005

Business license